Sirolimus- vs. Paclitaxel-Eluting Stents in Diabetic Patients

A randomized comparison favored SES.

Compared with patients without diabetes, diabetic patients are at increased risk for restenosis and adverse cardiac events after percutaneous coronary intervention and have been shown to derive particular advantage from drug-eluting stents. In this multicenter study, 400 diabetic patients undergoing PCI in Korea were randomly assigned to treatment with either sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES).

Baseline clinical, anatomic, and procedural characteristics were similar in the two groups. Angiographic measures were obtained in 82% of participants at 6 months. The primary endpoint of in-segment binary angiographic restenosis occurred in 4% of SES recipients and 21% of PES recipients (P<0.001). Mean late lumen-diamet…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)